PopularNew
BPC + TB4 combo
$89.99
★ Popular
RESEARCH USE ONLY (RUO) — FOR IN-VITRO LABORATORY RESEARCH
The Peptide JourneyResearch-based Podcast
ALLUVI Retatrutide 40 mg PenAll research episodesListen
Rated: 4.8/5
Trusted by customers with 4.8/5 average rating.
ALLUVI Retatrutide 40 mg Pen
Trusted by customers with 4.8/5 average rating.$249.99
Retatrutide (LY3437943) is an investigational peptide studied for activity at GIP, GLP-1 and glucagon receptors. The ALLUVI HEALTHCARE presentation is labeled 40 mg (4 doses of 10 mg) and is marked for refrigerated storage at 2°C–8°C. Published compound research does not establish the composition, purity or performance of this branded presentation.
For laboratory research use only — Research Use Only (RUO).
- Buy 2+ for $242.49 each and save 3%
- Buy 3+ for $237.49 each and save 5%
- Buy 5+ for $224.99 each and save 10%
- Buy 10+ for $212.49 each and save 15%
Direct from manufacturer to researcher
Shipping options confirmed at checkout
For laboratory research only
NEWAdvanced Laboratory Testing
HPLC Testing
Endotoxin Assay
TYMC Test
TAMC Test
Heavy Metal ScreeningCharacteristics
| Brand | ALLUVI HEALTHCARE |
|---|---|
| Presentation | Retatrutide pen and box |
| Label amount | 40 mg (4 × 10 mg) |
| Storage label | 2°C–8°C |
| Research compound | Retatrutide (LY3437943) |
| CAS Number | 2381089-83-2 |
| Molecular Formula | C221H342N46O68 |
| Molar Mass | 4731.34 g/mol |
| Receptor targets | GIP, GLP-1 and glucagon |
| Status | Investigational; not an approved medicine |
| Batch documentation | Product-specific COA, formulation and storage conditions pending confirmation |
How does ALLUVI Retatrutide 40 mg Pen work?
Published research describes retatrutide as a triple-hormone-receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors. These findings describe the investigational molecule, not verified results for the ALLUVI pen.
Handling & Safety
For laboratory research only — Research Use Only (RUO). Do not use the packaging illustration as administration, dosing or storage guidance. Obtain the product-specific safety data sheet, certificate of analysis and validated handling and storage instructions before laboratory use. Follow institutional safety procedures and wear appropriate protective equipment.
Summary
The ALLUVI HEALTHCARE 40 mg retatrutide pen presentation, listed alongside the 77 Peptides 77Reta-40 pen. Scientific references are provided below.
Resource
- NEJM — Triple–Hormone-Receptor Agonist Retatrutide for Obesity
- ClinicalTrials.gov — TRIUMPH-1 (NCT05929066)
- KEGG — Retatrutide chemical identification
All products on this site are for research and development use only. All products are Research Use Only (RUO). Neither the statements nor the products offered are intended to diagnose, treat, cure, or prevent any disease.
77 PEPTIDES RESEARCH
Peptide Research Insights
From the discoveries of 1977 to the next chapter in peptide science.
Explore research insights
